Cytokinetics Heart Drug’s Trial Data Look Competitive With BMS Med Camzyos

An experimental drug from Cytokinetics has shown promising Phase 3 results in improving heart function during exercise for patients with obstructive hypertrophic cardiomyopathy (oHCM), a rare cardiovascular disease. The drug, aficamten, demonstrated a significant increase in peak oxygen uptake compared to a placebo and had a consistent treatment effect across patient subgroups. The drug works by stabilizing the heart muscle protein myosin to prevent excessive contractions. In comparison to a similar drug on the market, aficamten showed a potential advantage in terms of safety profile and could support a less restrictive Risk Evaluation and Mitigation Strategy program. The full results of the study will be presented at an upcoming medical conference.

Source link

error: Content is protected !!